0001104659-20-091450.txt : 20200806 0001104659-20-091450.hdr.sgml : 20200806 20200806161629 ACCESSION NUMBER: 0001104659-20-091450 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200805 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 582301143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31812 FILM NUMBER: 201081868 BUSINESS ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 BUSINESS PHONE: 2186343500 MAIL ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 FORMER COMPANY: FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19991228 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 8-K 1 tm2026769d2_8k.htm FORM 8-K
0001023024 false 0001023024 2020-08-05 2020-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2020

 

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-31812 58-2301143
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

210 Main Street West

Baudette, Minnesota

  56623
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (218) 634-3500

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class: Trading Symbol(s): Name of each exchange on which registered:
Common Stock ANIP Nasdaq Stock Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On August 5, 2020, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from four to six members and appointed Antonio Pera and Jeanne Thoma as directors of the Company, effective immediately. In addition, the Board has appointed Mr. Pera to serve as a member of the Compensation Committee of the Board and has appointed Ms. Thoma to serve as a member of the Audit and Finance Committee of the Board. The Board has determined that Mr. Pera and Ms. Thoma are each independent in accordance with the applicable rules of the Nasdaq Stock Market.

 

In connection with their appointment, Mr. Pera and Ms. Thoma each received an initial equity award under the Company’s Sixth Amended and Restated 2008 Stock Incentive Plan (the “Plan”) comprised of (i) restricted stock (“Restricted Stock”) under the Plan and (ii) options to purchase common stock of the Company (the “Options”) under the Plan, having a total grant date fair value equal to $435,000 and each of which shall vest in two equal installments on the first anniversary and second anniversary of each of Mr. Pera’s and Ms. Thoma’s appointment to the Board, subject to continued service as a director of the Company. Each will also receive cash compensation for their service on the Board and Board committees in accordance with the cash compensation previously determined for the other non-employee members of the Board, in each case prorated based on their initial appointment date. Mr. Pera and Ms. Thoma will each enter into an indemnification agreement with the Company substantially in the form filed as Exhibit 10.30 to the Company’s Annual Report on Form 10-K for the 2007 fiscal year filed with the Securities Exchange Commission on March 17, 2008.

 

There are no arrangements or understandings between either Mr. Pera or Ms. Thoma and any other person pursuant to which either of them was appointed as a director of the Company, and there is no family relationship between either Mr. Pera or Ms. Thoma and any of the Company’s other directors or executive officers. In addition, Mr. Pera does not have an interest in any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1934, as amended. Ms. Thoma is the Chief Executive Officer of SPI Pharmaceuticals, Inc. (“SPI”), which supplies ingredients to the Company. The Company made payments totaling approximately $208,000 and $231,000 in fiscal year 2019 and the current fiscal year (as of July 23, 2020), respectively, to SPI.

 

Item 7.01 Regulation FD Disclosure

 

The press release announcing the appointment of Mr. Pera and Ms. Thoma to the Board is furnished as Exhibit 99.1 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit Description
99.1 Press release dated August 6, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ANI PHARMACEUTICALS, INC.  
 

  

 
     
  By:   /s/ Stephen P. Carey  
    Stephen P. Carey  
    Vice President, Finance and Chief Financial Officer  
Dated:  August 6, 2020    

 

 

 

 

 

 

 

 

EX-99.1 2 tm2026769d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE

 

 

ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors

 

Additions reflect ANI’s commitment to broaden pharmaceutical industry experience on Board

 

BAUDETTE, Minn., August 6, 2020 – ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the appointments of Jeanne Thoma, President and Chief Executive Officer of SPI Pharma, Inc. and Antonio (“Tony”) Pera, former President of Par Pharmaceutical to the ANI Pharmaceuticals Board of Directors. These appointments are effective immediately and increase ANI’s Board of Directors to seven members, including Nikhil Lalwani, who will join the Board next month when he starts as President and CEO of the Company on September 8, 2020.

 

These appointments represent a continuation of ANI’s efforts to broaden the scope of industry experience on the Board of Directors, as well as to bring forth more unique perspectives through enhanced diversity.

 

“As we pursue our dual goals of expanding the pharmaceutical industry expertise and broadening the diversity of our Board of Directors, we are pleased to welcome Jeanne and Tony to ANI. Jeanne brings demonstrated product development and commercialization success including extensive experience in pharmaceutical operations and pharmaceutical supply chain experience. Her talent for process innovation and optimization will help to guide our future growth. Tony’s strong background in generics sales, marketing, operations and significant product launch experience further adds to the Board’s depth. With the addition of our new President and CEO, Nikhil Lalwani, ANI is well positioned for future growth,” stated Patrick D. Walsh, Chairman of the Board of Directors.

 

“We greatly value the feedback shared with us and are committed to responding to the concerns raised by our stockholders during the 2020 annual meeting season, which included a commitment to diversity on our Board,” concluded Walsh.

 

Ms. Thoma is currently President and CEO of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. During her 30-year career, she has successfully built high-performing businesses that are agile, innovative and consistently deliver results. Prior to SPI, Ms. Thoma held positions of increasing responsibility at Lonza AG, a Switzerland-based biotech company, most recently as President and COO of the Microbial Control Business Sector. Prior to joining Lonza, Ms. Thoma spent 14 years at BASF Corp. in the Pharma Solutions business where she held various leadership positions in Sales, Marketing and Operations. Ms. Thoma is a member of the Board of Advisors for the Drug Chemical and Associated Technologies Association (DCAT).

 

 

 

 

Mr. Pera is a seasoned pharmaceutical industry leader with 40 years of experience. He retired as President of Par Pharmaceutical, the fifth-largest generic manufacturer in the United States, which is now part of Endo International, plc. Prior to Par, Mr. Pera held leadership positions at AmerisourceBergen, American Pharmaceuticals Partners, Bedford Laboratories, a division of Ben Venue Laboratories, and Baxter Healthcare. His breadth of experience spans sales, marketing, supply chain operations, and licensing, and he has played a pivotal role in the successful growth and commercialization efforts at several successful pharma entities.

 

About ANI

 

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.

 

Forward-Looking Statements

 

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the future growth of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.

 

Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to onboarding and integrating the additions to the Board and management team; implementing its strategic and tactical plans; importing raw materials; competition from other products; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions, including the ongoing impact of COVID-19; market trends; products development; regulatory and other approvals and marketing.

 

More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission ("SEC"), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

SOURCE: ANI Pharmaceuticals, Inc.

 

 

 

EX-101.SCH 3 anip-20200805.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anip-20200805_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anip-20200805_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 7 tm2026769d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001023024 2020-08-05 2020-08-05 iso4217:USD shares iso4217:USD shares 0001023024 false 8-K 2020-08-05 ANI PHARMACEUTICALS, INC. DE 001-31812 58-2301143 210 Main Street West Baudette MN 56623 218 634-3500 Common Stock ANIP NASDAQ false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Aug. 05, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 05, 2020
Entity File Number 001-31812
Entity Registrant Name ANI PHARMACEUTICALS, INC.
Entity Central Index Key 0001023024
Entity Tax Identification Number 58-2301143
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 210 Main Street West
Entity Address, City or Town Baudette
Entity Address, State or Province MN
Entity Address, Postal Zip Code 56623
City Area Code 218
Local Phone Number 634-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ANIP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://anipharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2026769d2_8k.htm anip-20200805.xsd anip-20200805_lab.xml anip-20200805_pre.xml tm2026769d2_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2026769d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2026769d2_8k.htm" ] }, "labelLink": { "local": [ "anip-20200805_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "anip-20200805_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "anip-20200805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "anip", "nsuri": "http://anipharmaceuticals.com/20200805", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2026769d2_8k.htm", "contextRef": "From2020-08-05to2020-08-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://anipharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2026769d2_8k.htm", "contextRef": "From2020-08-05to2020-08-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-20-091450-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-091450-xbrl.zip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